The Professional Home for Oncology Nurses

Advancements in understanding the long-term health effects of chemotherapy have led to more rigorous safety protocols, including enhanced personal protective equipment, widespread use of closed-system transfer devices, specialized chemotherapy disposal systems, and spill kits. ONS guidelines serve as the foundation for policies, procedures, and nursing education, ensuring the safety of oncology nurses. 

Artificial intelligence (AI) can help oncology nurses bridge the gaps engendered by the mental health crisis. Patients can access mental health resources on demand, and generative AI platforms (e.g., ChatGPT) can offer real-time coping strategies for managing stress. 

States with higher levels of vulnerability and larger minority populations have fewer than 4 available clinical trials per 100,000 people with gynecologic cancers than states with majority White populations, researchers reported in study findings published in JAMA Network Open. The results underscore the need to increase clinical trial availability in underserved areas and groups.

The cyclin-dependent kinase (CDK) inhibitor 2A (CDKN2A) is a tumor suppressor gene. The CDK4 gene makes a protein for cell division that enables cells to progress from the G₁ to S phase of the cell cycle. Pathogenic variants may cause cells to divide too quickly or in an uncontrolled way. CDK4 pathogenic variants are extremely rare.

Concluding an oncology nursing career that spanned more than five decades, ONS Chief Executive Officer Brenda M. Nevidjon, MSN, RN, FAAN, today announced her intent to retire in December 2025. She has led the Society as CEO since September 2014.

On February 14, 2025, the U.S. Food and Drug Administration (FDA) approved vimseltinib (Romvimza^™), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection would potentially worsen functional limitation or severe morbidity.